What is Helix?
Helix operates at the critical intersection of clinical diagnostics and population-scale genomic research. By leveraging one of the world's largest CLIA/CAP next-generation sequencing laboratories and its proprietary Exome+ assay, the company provides a comprehensive infrastructure for health systems, life sciences organizations, and payers. Helix's platform facilitates essential functions such as patient recruitment, clinically actionable disease screening, and the return of results, effectively accelerating the adoption of precision medicine in standard clinical workflows. The firm's market position is defined by its ability to scale complex genomic operations while maintaining the rigorous standards required for translational research and patient-facing healthcare applications.
How much funding has Helix raised?
Helix has raised a total of $383M across 4 funding rounds:
Series A
$100M
Series B
$200M
Grant
$33M
Series C
$50M
Series A (2015): $100M with participation from Illumina, Warburg Pincus, and Sutter Hill Ventures
Series B (2018): $200M led by Kleiner Perkins Caufield & Byers, Sutter Hill Ventures, Draper Fisher Jurvetson (DFJ), Illumina, Warburg Pincus, and Mayo Clinic
Grant (2020): $33M supported by U.S. National Institutes of Health (NIH)
Series C (2021): $50M featuring Temasek, DFJ Growth, Mayo Clinic, Kleiner Perkins, and Warburg Pincus
Key Investors in Helix
Illumina
Illumina is a global leader in sequencing and array-based solutions, providing the core technology and instrumentation necessary for advanced genetic and genomic analysis.
Warburg Pincus
Warburg Pincus is a premier global private equity firm that specializes in growth investing, providing strategic capital and operational expertise to companies across diverse market cycles.
Kleiner Perkins
Kleiner Perkins is a renowned venture capital firm that supports early and growth-stage companies in the technology and life sciences sectors through deep operational and financial backing.
What's next for Helix?
Following its latest capital injection, Helix is well-positioned to expand its footprint in the clinical genomics landscape. The company's strategic roadmap likely involves deepening its integration with major health systems and enhancing its translational research capabilities. By utilizing this recent investment, Helix aims to further refine its population genomics platform, potentially scaling its sequencing throughput and broadening the scope of its disease screening offerings. As the demand for data-driven clinical insights grows, Helix's focus on actionable genomic intelligence will be pivotal in maintaining its competitive advantage and driving long-term value for its stakeholders and the broader healthcare ecosystem.
See full Helix company page
